Phathom Pharmaceuticals, Inc. PHAT Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Phathom Pharmaceuticals, Inc.'s operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s operating lease liabilities (total)?
- Phathom Pharmaceuticals, Inc. (PHAT) reported operating lease liabilities (total) of $2.63M in Q1 2026.
- How has Phathom Pharmaceuticals, Inc.'s operating lease liabilities (total) changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s operating lease liabilities (total) increased by 731.6% year-over-year, from $316K to $2.63M.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s operating lease liabilities (total)?
- Over 5 years (2020 to 2025), Phathom Pharmaceuticals, Inc.'s operating lease liabilities (total) has grown at a 6.0% compound annual growth rate (CAGR), from $2.03M to $2.71M.
- What does operating lease liabilities (total) mean?
- This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.